Connect with us

Technology

Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis

Published

on

NASHVILLE, June 28, 2023 /PRNewswire/ — Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3, a groundbreaking anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis. This milestone marks a significant step forward in the development of advanced treatment options for individuals affected by this chronic and debilitating skin condition.

The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of safety.

Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1). Despite the availability of various treatment options, there remains an unmet need for more effective and safer therapies. With this topical formulation of AMTX-100 CF3, Amytrx Therapeutics aims to revolutionize the treatment landscape and offer hope to those living with atopic dermatitis.

The Phase 2b clinical trial will continue to build upon a recent trial that has evaluated the safety and efficacy of AMTX-100 CF3 in a larger cohort of adult patients that has shown favorable efficacy bypassing the need for rescue steroid treatment. This randomized, double-blind, placebo-controlled study will be conducted at 8-10 clinical sites across the country. This study is seeking 60 participants to generate a 1:1 ratio between placebo and active arms of the study. The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of treatment safety.

This clinical trial will include a 28-day treatment period with twice daily treatment and a 2-week follow-up assessment post-treatment to determine therapeutic efficacy. In addition, participants will receive a topical emollient 2-weeks prior to trial to exclude participants who may be impacted by a placebo effect. Precision medicine techniques will also be used to assess changes in the expression of genes involved in inflammation.

“We are thrilled to initiate the open enrollment for our Phase 2b clinical trial of AMTX-100 CF3,” said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics. “At Amytrx, we are committed to developing innovative therapies that can make a meaningful difference in the lives of patients. This trial represents a crucial step towards bringing a safe and targeted treatment option to adults suffering from atopic dermatitis, in addition to other chronic inflammatory skin diseases such as psoriasis, vitiligo, lupus, graft vs. host, and more.”

Amytrx Therapeutics has invested years of research and development into the creation of AMTX-100 CF3. This unique topical formulation of their anti-inflammatory peptide has shown promising results in preclinical and clinical studies. AMTX-100 CF3 utilizes a novel untapped intracellular target to control inflammation. The company believes that AMTX-100 CF3 has the potential to provide durable relief, enhance quality of life, and minimize the burden of this chronic condition with a revolutionary approach that interacts with a key checkpoint in the initiation of inflammation.

The open enrollment for the Phase 2b clinical trial of AMTX-100 CF3 is now underway. Eligible adults interested in participating or learning more about the trial are encouraged to visit the ClinicalTrials.Gov listing # NCT04313400 or visit Amytrx Therapeutics’ website at www.amytrx.com. The company welcomes collaboration with research institutions that wish to contribute to advancing the knowledge and treatment of other inflammatory skin disorders.

The current topical formulation of AMTX-100 CF3 being studied in the Phase 2b clinical trial provides an example of the various formulations available for novel anti-inflammatory peptide AMTX-100. Amytrx Therapeutics is actively exploring other delivery methods to cater to the diverse needs of patients across a variety of inflammatory diseases. These formulations include oral, injectable, nasal spray, and other options. This comprehensive approach underscores Amytrx Therapeutics’ commitment to developing a range of therapeutic options that can effectively target inflammation and provide additional treatment strategies.

About Amytrx Therapeutics

Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world’s most debilitating diseases. For further information, please visit www.amytrx.com

Kapur, S., Watson, W., & Carr, S. (2018). Atopic dermatitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 52. https://doi.org/10.1186/s13223-018-0281-6

View original content to download multimedia:https://www.prnewswire.com/news-releases/amytrx-therapeutics-announces-open-enrollment-for-phase-2b-clinical-trial-of-amtx-100-cf3-a-promising-anti-inflammatory-peptide-therapeutic-for-atopic-dermatitis-301866172.html

SOURCE Amytrx Therapeutics

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

The Hottest Dog Bronchial Health Supplement on Shopee in 2024

Published

on

By

SEOUL, South Korea, Nov. 10, 2024 /PRNewswire/ — As a dog owner, you may have often heard your furry friend coughing, whether it’s a dry hack or a honking sound. Though it might seem trivial, these coughs can cause serious discomfort for your furry friend and create anxiety for you as a caring pet parent.

DOCTORBY’s BREATH CARE is a nutritional supplement designed to support bronchial health in dogs, currently gaining attention among many pet owners on Shopee.

Coughing in dogs can be triggered by various factors, including temperature fluctuations, strong air conditioning, and dust or debris inhaled during walks. Additionally, as dogs age, their bronchial immunity can weaken, leading to potential health issues.

BREATH CARE contains a blend of functional ingredients like the plant-based complex extract TF-343, magnesium, and propolis, which can help alleviate respiratory issues such as coughing and support the elimination of waste accumulated in the bronchial passages.[1] With a taste dogs love, it doubles as a treat, making it incredibly easy for pet owners to administer. Furthermore, it has passed heavy metal and toxicity tests, ensuring safety without the use of synthetic sweeteners or colorings.

Currently, BREATH CARE ranks as one of the top products in Shopee’s pet nutrition and supplement category. In May 2024, it achieved the number one sales position in the pet nutrition category on Shopee Singapore, garnering immense popularity. Shopee has reported a staggering 3,000% growth in sales compared to 2023. Notably, DOCTORBY has not only topped the charts on Shopee but has also held the number one position on Amazon Japan for 22 consecutive weeks, establishing itself as a leader in the South Korean pet nutrition market and rapidly expanding in the global market.

For cat owners, the cat-specific bronchial supplement, CAT BREATH CARE, is also enjoying tremendous popularity. Additionally, DOCTORBY offers a variety of health supplements, including ‘SKIN & COAT’ for skin support, ‘EYES CARE’ for eye health and tear stain improvement, and ‘HAIRBALL CARE’ to assist with hairball elimination in cats. In Singapore, DOCTORBY products are exclusively available on Shopee.

Enjoy fast delivery via Shopee’s reliable fulfillment services, with most orders arriving within 2 to 3 days for a satisfying shopping experience. Shopee also hosts monthly promotional events, such as Double Day and Pay Day, offering a range of exciting deals. Moreover, a special Mega Day event is planned for November 11, promising additional benefits for shoppers.

[1] Korean J. Food Sci. Technol. Vol.35, no.5, pp980-987 (2003)

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/the-hottest-dog-bronchial-health-supplement-on-shopee-in-2024-302299805.html

SOURCE DOCTORBY

Continue Reading

Technology

LG Display Succeeds in Developing World’s First Stretchable Display that Expands by 50 Percent

Published

on

By

SEOUL, South Korea , Nov. 9, 2024 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced today its unveiling of the world’s first Stretchable display capable of expanding up to 50%, the highest rate of elongation in the industry. At LG Science Park in Seoul on Nov. 8, the company demonstrated the panel at a meeting of more than 100 South Korean industry, academia, and research stakeholders involved in a Stretchable display national project.

Stretchable displays are seen as the ultimate free-form screen technology because they can be freely transformed into any shape, including by stretching, folding, and twisting.

The new prototype features a 12-inch screen that stretches up to 18 inches, while simultaneously delivering a high resolution of 100ppi (pixels per inch) and full red, green, and blue (RGB) color.

Compared to the first Stretchable display prototype unveiled in 2022, the new panel’s maximum elongation rate has more than doubled from 20% to 50%. This enhanced stretchability enables various display design possibilities, raising the technology’s potential competitiveness when commercialized.

By applying a number of new technologies, such as improving the properties of a special silicon material substrate used in contact lenses and developing a new wiring design structure, LG Display improved the panel’s stretchability and flexibility, exceeding the original national project’s target of 20% elongation.

In addition, by using a micro-LED light source of up to 40μm (micrometers), the new prototype’s strengthened durability means it can be repeatedly stretched over 10,000 times, maintaining clear image quality even in extreme environments such as exposure to low or high temperatures and external shocks.

Stretchable displays are not only thin and lightweight but also capable of adhering to irregularly curved surfaces like clothing and skin. They are expected to be widely applied in various industries, from fashion and wearables to mobility.

The company showcased numerous concepts for the application of Stretchable displays, including an automotive panel that stretches out into a convex shape and can be operated by hand as well as a wearable display attached to firefighters’ uniforms that provides real-time information.

LG Display was selected as the lead company for the national project to develop Stretchable displays in 2020 and since then has been conducting joint R&D with 19 domestic industry and research institutes. It is one of the major tasks of a wider project to develop core technologies for next-generation displays promoted by South Korea’s Ministry of Trade, Industry and Energy (MOTIE) along with the Korea Planning & Evaluation Institute of Industrial Technology.

By successfully completing the project, LG Display has not only secured core technologies that can lead the next-generation display market but also contributed to localizing materials, components, and equipment as well as building an R&D infrastructure.

“We will continue to build a sustainable future display ecosystem through close cooperation between South Korean industry, academia, and research stakeholders,” said Soo-young Yoon, CTO and Executive Vice President of LG Display.

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Manager, Communication Team
Email: hjy05@lgdisplay.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lg-display-succeeds-in-developing-worlds-first-stretchable-display-that-expands-by-50-percent-302300599.html

SOURCE LG Display

Continue Reading

Technology

Stay Better in China: Tell the Beautiful China to the World

Published

on

By

NANCHANG, China, Nov. 9, 2024 /PRNewswire/ — A report from Jiangxi International Communication Center (JXICC): Komurcu Busra, an international student from Nanchang University, talks about her life in China. She felt the simplicity of Chinese countryside and pure beauty of nature here. She wants to tell the beautiful China to the world.

https://www.youtube.com/watch?v=vQGbRJc4ncc

View original content to download multimedia:https://www.prnewswire.com/news-releases/stay-better-in-china-tell-the-beautiful-china-to-the-world-302277393.html

SOURCE Jiangxi International Communication Center(JXICC)

Continue Reading

Trending